Mink Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Mink Therapeutics

19/03/2024 12:33

* Mink Therapeutics Inc  INKT.OQ   INKT.O  is expected
to show no
change in quarterly revenue when it reports  results on March 21
for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Mink Therapeutics Inc is
for a
loss of 15 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $8.00​, above​ its last closing price of $0.86. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.18       -0.18      -0.15     Beat    17.8
 Jun. 30 2023  -0.19       -0.20      -0.18     Beat    8.9
 Mar. 31 2023  -0.25       -0.24      -0.17     Beat    28.4​
 Dec. 31 2022              -0.21      -0.23     Missed  -9.5
 ​​Sep.        -0.23       -0.23      -0.19     Beat    18.3
 30 2022                                                
 Jun. 30 2022  -0.24       -0.24      -0.18     Beat    25​
 Mar. 31 2022  -0.21       -0.21      -0.23     Missed  -11.3
 Dec. 31 2021  -0.41       -0.41      -0.18     Beat    56.1
 This summary was machine generated March 19 at 12:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)